Celgene, Lannett cancer, generics news

The U.S. District Court of the Eastern District of Pennsylvania denied a motion by Celgene to dismiss a case brought by generics company Lannett seeking to require Celgene to provide Lannett with enough Thalomid thalidomide to conduct bioequivalence studies. The studies